

# Effectiveness of Treatment Modalities on Kidney Stone Recurrence

Anna L. Zisman

## Abstract

Nephrolithiasis is highly prevalent across all demographic groups in the Western world and beyond, and its incidence rates are rising. In addition to the morbidity of the acute event, stone disease often becomes a lifelong problem that requires preventative therapy to diminish ongoing morbidity. Across the majority of stone types, increased fluid intake and targeted dietary modifications are mainstays of therapy. Specific dietary interventions associated with reduced calcium stone risk include adequate dietary calcium intake and restriction of sodium, protein, and oxalate intake, among others. Pharmaceutical therapy may be required if lifestyle changes are insufficient to minimize risk of stone recurrence, and must be targeted to the specific metabolic abnormalities portending risk for a given patient. Therapeutic options for idiopathic calcium stone disease include thiazides, citrate salts, and uric acid–lowering agents. Alkali salts are also the treatment of choice for uric acid stone disease. Management of struvite stone disease is largely surgical, but acetohydroxamic acid is a proven second line therapy. Cystinuria requires lifestyle modifications and may call for thiol-binding agents. Significant heterogeneity of the clinical population with stone disease has previously limited opportunities for large randomized controlled trials. However, as clinical phenotypes and genotypes are increasingly clarified, there are mounting opportunities for targeted randomized controlled trials in stone prevention. In the meantime, the currently available evidence for both lifestyle and pharmacologic interventions is reviewed herein.

*Clin J Am Soc Nephrol* 12: 1699–1708, 2017. doi: <https://doi.org/10.2215/CJN.11201016>

Section of  
Nephrology,  
Department of  
Medicine, University  
of Chicago, Chicago,  
Illinois

**Correspondence:**  
Dr. Anna L. Zisman,  
Section of  
Nephrology,  
Department of  
Medicine, University  
of Chicago, 5841 S.  
Maryland Avenue,  
MC5100, Chicago, IL  
60637. Email:  
[azisman@medicine.  
bsd.uchicago.edu](mailto:azisman@medicine.bsd.uchicago.edu)

## Introduction

Kidney stone disease is highly prevalent in the United States, affecting one in 11 individuals during their lifetime (1). Rates of nephrolithiasis in the United States population are increasing in adults and children, as well as across demographic groups, with National Health and Nutrition Examination Survey (NHANES) data reflecting a 70% increase in disease prevalence in the general population (from 5.2% in the 1988–1994 dataset to 8.4% in the NHANES 2007–2010 dataset) over the last 15 years (1). Nephrolithiasis is currently the most expensive urological condition, estimated to cost the health care system more than \$10 billion per year (2), not accounting for time lost from work. Because of the concurrent epidemics of obesity, metabolic syndrome, and diabetes (all independently associated with increased risks of stone formation [3–5]) as well as anticipated population growth, current projections estimate costs due to stone disease to rise by \$1.24 billion per year by 2030 (6). Emergency department (ED) visits for stones have increased by 91% between 1992 and 2009 (7). More than 10% of patients initially evaluated in the ED require a return visit in <30 days, further exacerbating costs and reflecting high patient morbidity (8). Quality of life measures are significantly lower in individuals suffering from nephrolithiasis than in the general population (9).

Nephrolithiasis is often a recurrent and lifelong disease, with recurrent stone episodes predicting even

higher future recurrence rates and worse clinical outcomes (10). Precise estimates of recurrence rates are difficult to ascertain given clinical heterogeneity, but a recent retrospective cohort of more than 2200 first-time stone formers in Olmstead County noted that stone recurrence rates at 2, 5, 10, and 15 years were 11%, 20%, 31%, and 39%, respectively (11). Data from clinical trials of stone therapies that included recurrent stone formers suggest recurrence rates between 40% and 45% in untreated recurrent stone formers in the control groups in the thiazide trials (12–15), and up to 80% in the citrate trials at 3 years (16–18). Given the very high recurrence rates, treatment aimed at prevention of stone formation is critical to diminishing the morbidity and costs associated with the disease.

## Treatment Options in Kidney Stone Prevention

The available treatment options for prevention of stone recurrence can be divided into lifestyle interventions and pharmaceutical therapies. In practice, a combination of therapies is most effective, but for the purposes of this discussion we will evaluate each independently. In this review we will also limit our focus to idiopathic stone disease, whether calcium or uric acid except as noted, and will not include commentary on secondary causes of stone disease such as primary hyperparathyroidism or bowel disease.

## Lifestyle Interventions

### Effect of Fluid Intake on Urinary Stone Recurrence

Regardless of the specific stone type, stone formation requires urine supersaturation (SS) with respect to stone-forming salts such as calcium oxalate or calcium phosphate (CaP), to allow crystal formation and stone growth. The most significant determinant of SS is urine volume, as concentrations of stone-forming salts vary with volume (19,20). Although multiple observational studies, including national cohorts (21–24) and individual kidney stone center experiences (25–27), have demonstrated the critical importance of increased urine volume in prevention of stone recurrence, there has been only one randomized controlled trial evaluating the role of increased fluid intake on prevention of recurrent stones. Borghi *et al.* (19) randomized 199 Italian participants after their first idiopathic calcium stone episode to either increased water intake with a goal of 2.0 L of urine volume daily, which the patients were instructed to measure at home every 2–3 months, or to no therapy. After 5 years of follow-up, the group randomized to increased fluid intake had a significantly lower stone recurrence rate of 12%, compared with 27% in the control group. Notably, the mean attained urine volume in the group without a recurrence was 2.6 L, compared with 1 L in controls. On the basis of this limited literature, national guidelines (20,28) have adopted recommendations for encouraging increased fluid intake to facilitate at least 2.5 L of urine volume to prevent recurrence of stone disease. More recently, a large meta-analysis has confirmed a dose-dependent response to increased water intake, with every 500 ml of increased intake associated with a significant decrease in stone formation (29). It is important to note a key limitation of the literature, however, as Borghi *et al.* studied first-time stone formers with no residual disease burden on imaging obtained after the acute event. This is not representative of the stone-forming population in general, as recurrence is common, and residual stone burden after stone passage or postprocedure is known to predict a significantly higher rate of recurrence (11,30,31). There are thus no randomized controlled trial data in the population at highest risk of recurrence and in those with highest morbidity from the disease.

A few general points warrant attention, as patients are often counseled broadly to increase their fluid intake without regard for potential pitfalls. First, although it is clear that higher fluid intake increases urine volume and thereby decreases urine SS, generalized fluid intake targets do not account for the interindividual variability in the urinary excretion of other contributors to stone risk such as calcium, oxalate, and uric acid, or the presence of adequate quantities of crystallization inhibitors such as citrate. A more personalized approach using urine SS targets for a given stone type has never been prospectively tested, but this has been the approach in clinical practice at our institution for more than 40 years and has demonstrated durable prevention of stone recurrence (26). Second, a critical point that has never been studied in large trials is that for the majority of individuals, fluid intake is not evenly spaced throughout the course of the day because of work or school commitments, periods of exercise or sleep, and timing of meals. Data from studies

of stone formers demonstrate that SS varies throughout the day and is highest overnight (32). Furthermore, 24-hour urine measurements are able to demonstrate overall 24-hour urine volume, but do not provide sufficient granularity to ascertain whether periods of low urine volume, and therefore high urinary SS, exist and correlate to risk of stone recurrence. It is our practice to highlight the importance of spaced fluid intake throughout the course of the day to our patients, which has met with clinical success (26), but this approach has not been prospectively studied nor directly compared with a generalized fluid target.

Recent data suggest the importance of not only absolute fluid intake, but also potentially the type of fluids consumed. Using data from three large prospective cohorts with nearly 200,000 participants, Ferraro *et al.* (33) demonstrated the heightened incidence of stone disease with increasing sugar-sweetened cola consumption, potentially because of the higher fructose content. Artificially sweetened beverages did not portend higher stone risk, whereas increasing quantities of punch consumption were also linked to higher incidence of nephrolithiasis. The authors also noted a protective effect with higher consumption of coffee (caffeinated and decaffeinated), tea, red and white wine, beer, and orange juice (33), confirming their previous reports (34,35). Although lemon juice and lemonade are commonly recommended in popular culture for stone prevention because of their potential to increase urinary citrate, an inhibitor of calcium crystallization, prospective outcomes data for their use in stone prevention are lacking. Further, several studies (36–38) have noted increased urinary citrate when participants ingested 120 ml of lemon juice diluted in 2 L of water over the course of the day, the responses were either not durable or not associated with improvements in pH or urine SS. At this time, no data are available on stone event rates with this therapy.

Lastly, despite the published recommendations and evidence supporting its utility as an effective prevention mechanism for stone formers, achieving significant increases in hydration, and subsequently, urinary volumes remains a considerable clinical challenge (39). To date, adherence to increased fluid recommendations has generally been understudied, with little data assessing patient compliance specifically for fluid intake. However, non-compliance with metabolic treatment of nephrolithiasis is known to be as high as 30% (40,41). Parks *et al.* (42) evaluated the increases in 24-hour urine volumes on follow-up urine collections in clinical practice from 14 clinical sites that included both private and academic institutions. Physicians at all sites were recommended to counsel their patients to increase their fluid intake to facilitate at least 2 L of urine volume, although whether this occurred could not be verified. In more than 2800 patients across the sites, the mean increase in urine volume was only 0.31 L every 24 hours. For the clinician, targeting behavioral strategies to maintain consistent fluid intake is critical for the durable prevention of stone recurrence.

### Effect of Diet on Urinary Stone Events

Dietary risk factors are of critical importance in reducing the risk of stone formation. In the available studies, individual variables are often isolated to study risk and several will be reviewed independently below. However, it

is important to remember that humans consume food, not individual nutrients, and their interplay is likely to be important as well. For example, Taylor *et al.* (43) studied the effect of the Dietary Approaches to Stop Hypertension (DASH)-style diet (high in fruits, vegetables, low fat dairy, and nuts/low in sodium and processed meats) in a prospective manner among more than 240,000 patients in three large cohorts. Over a combined 50 years of follow-up across the three cohorts and more than 5600 incident stone events, the highest DASH scores were associated with a 40%–45% decreased risk of stone events.

In the pivotal randomized controlled trial in the literature evaluating the effect of a diet on stone recurrence, Borghi *et al.* (44) randomized 120 men with recurrent calcium oxalate stones and hypercalciuria to either a normal calcium (30 mmol/d), low animal protein (52 g/d), and low salt diet (50 mmol sodium chloride) or to a low calcium diet (10 mmol/d) and prospectively followed the participants for stone recurrence events over the course of 5 years. Both groups were advised on adherence to a low oxalate diet. The relative risk of recurrence of stone disease was 0.49 (95% confidence interval 0.24 to 0.98;  $P=0.04$ ) in the normal calcium, low animal protein, and low salt diet group. Importantly, although there is certainly a likely role of other nutrients in decreasing the risk of stone recurrence, the low sodium group had a significant decline in urinary calcium levels (while ingesting a higher calcium diet than the low calcium diet group), which was also reflected in the SS values for calcium oxalate. The ultimate dietary sodium intake achieved in the low sodium group (on the basis of 24-hour urine sodium measurements) was more than double the initial target of 50 mmol/d at 110–130 mmol/d, but significantly lower than the 200 mmol/d in the low calcium group. Although the urine volumes were similar in the two groups, urinary oxalate excretion was significantly higher over the course of the 5 years in the low calcium diet group, significantly contributing to the noted higher SS. This is not unexpected, as the higher dietary calcium intake facilitates gut oxalate binding, with less oxalate available for distal absorption and, ultimately, urinary excretion (45).

**Sodium.** The positive relationship between dietary sodium intake and urinary calcium excretion was first recognized by Kleeman *et al.* (46). In a study with healthy volunteers, an 82% increase in urinary calcium excretion was noted when dietary sodium intake was increased from 19 to 419 mEq/d. Subsequent sodium chloride-loading studies in healthy volunteers demonstrated a ratio of approximately 0.8 mmol calcium per additional 100 mmol of sodium ingested per day (40 mg of calcium per 6 g of salt intake) (47). Epidemiologic data have corroborated the documented physiologic relationship. In a large prospective study involving more than 90,000 healthy women, a significant trend in relative risk of stone disease along increasing quintiles of self-reported dietary sodium intake was noted (22), although others have not shown the same correlation (23,24).

Interestingly, experimental data suggest that idiopathic calcium stone formers are more sensitive to the effects of sodium intake on urinary calcium levels, suggesting that the effect of a decrement in dietary sodium would be more prominent in this group. For example, in a study of 14 hypercalciuric stone formers, increasing sodium intake from 213 to 276 mmol/d led to an increase of 11.1–13.3 mmol/d of calcium excretion (ratio of 3.5 mmol calcium

per additional 100 mmol sodium ingested per day) (48). Two other studies also found increased calcium/sodium ratios in hypercalciuric stone formers of 1.9 (49) and 2.1 (50). In addition to the negative effect on calcium excretion, Sakhaee *et al.* (51) demonstrated a 20% decrement in urinary citrate, a crystallization inhibitor known to protect against stone disease, when dietary sodium was increased from 50 to 300 mmol/d (along with a 44% increase in urinary calcium). Lastly, in a study of 210 hypercalciuric calcium stone formers randomized to either a low sodium or an *ad libitum* diet (with a background of 2–3 L of fluid intake and an 800–1000 mg calcium intake in both groups), Nouvenne *et al.* (52) demonstrated a significant decrease of urine calcium ( $432\pm 96$ – $271\pm 86$  mg/d) in the low sodium diet group, where urinary sodium decreased from  $228\pm 57$  to  $68\pm 43$  mmol/d at 3 months.

The physiologic studies, epidemiologic data, and the single randomized controlled study reviewed above underscore the role of excessive dietary sodium intake in lithogenesis. It should be briefly noted that all observational data are limited by potential confounders such as age, sex, ethnicity, and weight (typically adjusted for in multivariate analysis), as well as other variables that may not be accounted for, including total caloric intake, dietary sodium intake as a marker for an overall poor diet (with regard to fruits or vegetable intake or processed food), or health habits such as lack of exercise, for example. However, given the lack of harm of a moderate sodium diet, along with potential cardiovascular benefits, moderation of dietary sodium intake should be recommended to all stone formers. Targeting a dietary sodium intake  $<100$  mmol/d is a reasonable goal, on the basis of the data herein, and is supported by national guidelines (20).

**Calcium.** Historically, patients with calcium stone disease were advised to limit dietary calcium because it was thought to promote stone formation. The Borghi *et al.* (44) trial reviewed above convincingly demonstrated the increased risk of a low calcium diet, with the mechanism likely to be higher urinary oxalate when less dietary calcium is consumed. Additional support for the importance of dietary calcium comes from prospective observational cohorts (21–23), where those in the highest quintile of calcium intake, compared with the lowest, were more than 30% less likely to develop a stone. Slightly variable across the cohorts, the highest quintiles were generally  $>1000$  mg of daily calcium intake. Accordingly, guidelines recommend 1000–1200 mg of dietary calcium for calcium stone formers (20). Importantly, calcium supplements may not have the same benefits, as in one of the cohort studies, women taking supplements were 20% more likely to have a stone, although it is unclear whether supplement type (calcium carbonate versus calcium citrate) affects risk (22). The divergent effects may also be due to the timing of supplement ingestion, as when taken away from meal times the gut oxalate-binding effect may be negated.

**Oxalate.** The relative contribution of dietary oxalate to risk of stone formation remains controversial despite decades of study, due to multiple challenges such as difficulty in determining the precise content of oxalate in foods, the heterogeneity of patient populations studied, and the variability in gut oxalate absorption across populations and levels of dietary intake. High levels of urine oxalate have

also been linked to increased risk of stone formation (53,54), and in the general population of idiopathic calcium stone formers, up to 50% of patients have at least mild hyperoxaluria (55), defined as 24-hour urinary oxalate excretion >45 mg. In extreme form, patients with primary hyperoxalurias, the inborn errors of glyoxylate metabolism resulting in the overproduction of oxalate by the liver and profound hyperoxaluria, are well known to develop severe nephrolithiasis, nephrocalcinosis, and renal failure (56). Despite the frequency of hyperoxaluria in the stone-forming population, a large population-wide study has not documented a difference in intake of dietary oxalate between idiopathic calcium stone formers and the general population (57). Furthermore, in other large cohorts, dietary oxalate did not have a clinically significant effect on urinary oxalate excretion (58). In addition, multiple trials have failed to document a decrement in urinary oxalate excretion in response to a low dietary oxalate intake in stone formers (59–61), but others have suggested benefit (62–65). Although patients with calcium oxalate stone disease are often counseled to limit dietary oxalate intake, in the absence of hyperoxaluria, there is no evidence that this is helpful to prevent stone recurrence. In the presence of hyperoxaluria, it may be prudent to limit the intake of individual foods very high in oxalate, particularly in light of evidence that stone formers have a higher gut oxalate absorption (59). Notably, an adequate calcium intake of >1000 mg daily may mitigate the effect of dietary oxalate.

**Animal Protein.** In addition to the data from the Borghi *et al.* (44) trial indicating the benefit of a moderate protein diet for stone reduction, there are suggestions from prospective observational cohorts that, at least in men, there is a positive association between consumption of animal protein and new stone formation (21–23). Recent data have also linked the relative ratio of potassium intake to animal protein intake to lithogenic risk (66), presumably because potassium intake is associated with alkali loads. Protein intake is equivalent to an acid load, which lowers urine citrate excretion and increases urinary net acid excretion (67). As urinary net acid excretion is directly associated with urinary calcium excretion (67), it is not surprising that increasing dietary protein intake is associated with risk. However, in at least two randomized controlled trials comparing stone recurrence rates in participants advised on adherence to a low animal protein diet, a high fiber diet, or a standard diet, the authors were unable to demonstrate a difference in stone recurrence rates at 3.4–4 years of follow-up (68,69), although concerns have been raised that the control groups had a significantly higher fluid intake, which may explain the lack of effect.

### Pharmacologic Therapy

Knowledge of the specific stone type and the metabolic risk factors in a given patient allows for a targeted treatment strategy aimed at those abnormalities.

### Patients with Calcium Stones

Common abnormalities noted in calcium stone formers are hypercalciuria, hypocitraturia, and hyperuricosuria. Medical therapies aimed at each of these abnormalities are

available. The randomized controlled trials are summarized in Table 1.

### Hypercalciuria/Thiazides

Thiazide diuretics are the mainstay of therapy for patients who require lowering of urine calcium levels. The mechanism of calcium lowering in the urine appears to be increased proximal tubule calcium reabsorption (70,71), with resultant increase in serum calcium and likely increased flux of calcium into bone (72,73). There are at least ten randomized controlled trials in the literature assessing the efficacy of various thiazides on decreasing the rates of calcium stone recurrence in heterogeneous populations. Seven trials (12,13,15,74–77) have demonstrated a significant decrease in stone recurrence with thiazides over timeframes ranging from 2.1 to 5 years of use. Various agents were used including chlorthalidone (25–50 mg daily), bendroflumethiazide (2.5 mg three times a day), trichlormethiazide (4 mg daily), hydrochlorothiazide (25 mg twice a day, 50 mg daily, and 100 mg daily), and indapamide (2.5 mg daily), with the studies ranging in size from 22 to 175 participants. In all cases the participants were calcium stone formers, but only two of the studies focused specifically on calcium oxalate stone formers, whereas others allowed all calcium stone disease. The remaining three trials (78–80) that enrolled all calcium stone formers did not show evidence for decreased stone recurrence, but these studies were of significantly shorter duration (1–2 years). The proportion of patients with documented hypercalciuria in the ten studies ranged from 20% to 100%, somewhat complicating the interpretation of the results in the negative trials. Although no studies have specifically addressed the role of thiazides in patients with calcium stones without predefined hypercalciuria, given the continuous nature of risk with rising calcium excretion (53), one might predict that a risk-lowering benefit may manifest even in those without overt hypercalciuria as strictly defined.

If the clinician elects to use thiazides for their calcium-lowering effect, it is critical that they be dosed in a manner consistent with that used in the trial literature. According to at least one study, this is often not the case. Reviewing the use of thiazides for stone prevention at their institution, Vigen *et al.* (81) noted that of 107 patients in their cohort, 102 were treated with hydrochlorothiazide. However, only 35% were receiving dosages shown in the literature to be effective for stone prevention (at least 50 mg/d), with 52% receiving 25 mg daily and 13% receiving 12.5 mg daily. Four patients received indapamide and one received chlorthalidone at appropriate evidence-based dosing.

### Hypocitraturia and Calcium Oxalate Stone Formers/Citrate and Alkali Therapy

Patients with low urine citrate are at an increased risk for stone formation because citrate acts as an inhibitor of crystal formation, growth, and aggregation. Therapeutic options to treat hypocitraturia (outside of correcting underlying issues such as hypokalemia or systemic acidosis) are limited to alkali supplementation. Furthermore, citrate supplementation has also been shown to be effective in stone prevention for calcium oxalate stone formers

Table 1. Major clinical trials in pharmacotherapy of calcium nephrolithiasis

Author	Study Design	Enrollment Criteria (n)	Treatment	Duration, yr	Treatment/ Placebo, n	Recurrence Rate, % Treated/Placebo	Relative Risk (95% CI) or P Value
<b>Thiazide</b>							
Borghgi <i>et al.</i> (12)	RCT, DB	CaOx SF (75)	Indapamide 2.5 mg daily	3	43/14	15/43	P<0.001
Brocks <i>et al.</i> (78)	RCT, DB	CaSF (62)	Bendroflumethiazide 2.5 mg three times a day	1.6	33/29	24/16	P=0.45
Ettinger <i>et al.</i> (13)	RCT, DB	CaOx (73)	Chlorthalidone 25 or 50 mg daily	3	19/23/31	14/46	P<0.01
Fernández-Rodríguez <i>et al.</i> (77)	RCT	CaSF (100)	Hydrochlorothiazide 50 mg daily	3	50/50	NR	P=0.003
Laerum (14)	RCT, DB	CaSF (50)	Hydrochlorothiazide 25 mg twice a day	3	25/25	20/48	P=0.04
Mortensen <i>et al.</i> (80)	RCT, DB	CaSF (22)	Bendroflumethiazide 2.5 mg three times a day	2	12/10	40/40	P=1.0
Ohkawa <i>et al.</i> (15)	RCT	CaSF (175)	Tricloromethiazide 4 mg daily	2.1–2.2	82/93	NR	P<0.05
Robertson <i>et al.</i> (76)	RCT, DB	CaSF (22)	Bendroflumethiazide 2.5 mg three times a day	3.0–5	13/9	NR	P<0.01
Scholz <i>et al.</i> (79)	RCT, DB	CaSF (51)	Hydrochlorothiazide 25 mg twice a day	1	25/26	24/23	P=0.93
Wilson <i>et al.</i> (75)	RCT	CaSF (44)	Hydrochlorothiazide 100 mg daily	2.8	23/21	21/44	0.48 (0.07 to 0.92)
<b>Citrate</b>							
Barcelo <i>et al.</i> (16)	RCT, DB	HypoCit CaSF (57)	Potassium citrate 30–60 mEq daily	3	18/20	28/80	P<0.001
Ettinger <i>et al.</i> (17)	RCT, DB	CaOx SF (64)	Potassium magnesium citrate 60 mEq daily	3	31/33	13/64	0.16 (0.05 to 0.46)
Hofbauer <i>et al.</i> (18)	RCT, DB	CaOx SF (50)	Sodium potassium citrate to keep urine pH at 7–7.2	3	25/25	69/73	P=0.65
Lojanapivat <i>et al.</i> (83)	RCT	CaSF (76)	Potassium citrate 81 mEq daily	1	39/37	8/46	P<0.01
Soygür <i>et al.</i> (82)	RCT	CaOx SF (90)	Potassium citrate 50 mEq daily	1	46/44	0/32	P<0.05

95% CI, 95% confidence interval; RCT, randomized controlled trial; DB, double blind; CaOx, calcium oxalate; SF, stone former; CaSF, calcium stone former; HypoCit, hypocitratric; NR, not reported.

without hypocitraturia. To date, there are five studies in the literature focusing on supplementation with citrate salts, four of which showed a significant improvement in stone recurrence rates. In a double-blind placebo-controlled trial, Barcelo *et al.* (16) randomized 57 calcium stone formers with hypocitraturia (<643 mg/d) to either potassium citrate 30–60 mEq/d or placebo. At 3 years, stone growth or formation was documented in 14 out of 20 patients receiving the placebo and five out of 18 patients receiving citrate ( $P<0.001$ ). Ettinger *et al.* (17) randomized 64 calcium oxalate stone formers with active stone disease to either placebo or potassium magnesium citrate (42 mEq citrate, three times a day). At 3 years, new stone formation or growth of old stones was noted in 64% of the placebo patients and 13% of the treated patients. Soygür *et al.* (82) studied the efficacy of potassium citrate (50 mEq/d) versus placebo in prevention of post-extracorporeal shock wave lithotripsy residual fragment growth or new stone formation in 90 patients with calcium oxalate stone disease. At 1 year, no patients receiving citrate supplementation formed new stones or demonstrated evidence of residual fragment growth, whereas 14 out of 44 patients demonstrated new growth in the placebo group ( $P<0.05$ ). In a more recent study evaluating new stone or residual fragment growth after urologic intervention, Lojanapiwat *et al.* (83) randomized 76 calcium stone formers 8 weeks postprocedure to potassium citrate 81 mEq daily versus placebo. Approximately 40% of the patients in both groups were hypocitraturic (24-hour urine citrate <325 mg daily). At 1 year, in the group that was initially stone free, 92% of the citrate group versus 58% of the placebo group remained stone free. Of the group with residual fragments, 31% of the treatment group and 9% of the placebo group were stone free at 1 year. In the only negative citrate trial, Hofbauer *et al.* (18) randomized 50 calcium oxalate stone formers to either placebo or potassium sodium citrate dosing sufficient to maintain a urinary pH of 7–7.2. Given the pH targeting requirement, the study could not be double blinded. At 3 years, 16 out of 22 patients in the placebo group and ten out of 16 patients in the citrate group developed new stone formation ( $P=0.65$ ).

Classically, sodium salts are avoided in the treatment of stone disease because of concerns regarding increasing calcium excretion, as denoted previously, and there are no long-term prospective trials addressing long-term outcomes for stone recurrence. However, Pinheiro *et al.* (84) enrolled 16 adult hypocitraturic calcium stone formers in a randomized double-blind crossover trial comparing potassium citrate (60 mEq/d) and sodium bicarbonate (60 mEq/d) on a controlled diet, and evaluated 24-hour urinary parameters after 3 days on each drug. There were equivalent increases in urine citrate and pH with both agents, and despite an increase in urinary sodium with sodium bicarbonate, no increase in urinary calcium excretion was seen. However, therapy with potassium citrate resulted in a marked decrease in urinary calcium, as well as a more pronounced decrement in SS for calcium oxalate (CaOx). Although the efficacy data for alkali supplementation are highly encouraging, clinicians must assure regular monitoring of urine pH and SS for both CaOx and CaP in patients treated with alkalis, as the desired outcome of higher urine pH may lead to undesired increases in CaP (brushite) SS (84,85), which may lead to CaP stone formation.

### Hypocitraturia and CaP Stone Formers/Citrate and Alkali Therapy

In general, CaP stone formers are largely treated similarly to CaOx stone formers, with recommendations for increased fluid intake, dietary interventions as discussed above, and thiazides as necessary to modulate urinary calcium levels (20). As many of CaP stone formers have hypocitraturia and a higher urine pH at baseline, the role of alkali therapy is controversial and no prospective randomized controlled studies have specifically addressed the use of supplemental alkali therapy in this population. However, in at least two of the citrate trials (Table 1) the enrollment criteria did not specify the type of calcium stone and likely included participants with CaP nephrolithiasis (16,83). A small observational trial in nine participants with renal tubular acidosis, who typically form CaP stones, noted decreased risk of CaP stone formation with potassium citrate therapy (86). Increasing urinary citrate should decrease both brushite and hydroxyapatite crystallization, urine calcium, and overall SS for CaP, the benefits of which may be offset by a higher urine pH and increases in CaP SS (87). As noted for the CaOx stone formers, clinicians must maintain vigilance to assure appropriate risk parameters are maintained with therapy.

### Hyperuricosuria

Hyperuricosuria decreases the solubility of calcium oxalate *in vitro* and is felt to contribute to recurrence risk in calcium stone formers (88). However, recent epidemiologic data has questioned these assumptions, as a cross-sectional study of more than 3300 men and women across three large cohorts showed an inverse association between urine uric acid excretion and stone formation in men and younger women, but not in older women (89). Typically, dietary purine restriction is the initial therapeutic intervention in patients with hyperuricosuric calcium stone disease, as moderate protein restriction is warranted to decrease urinary calcium, but additional therapy may be required. In a randomized controlled trial of 60 hyperuricosuric calcium oxalate stone formers with normocalciuria, therapy with allopurinol demonstrated decreased risk for calcium stone recurrence and longer time to recurrence ( $P<0.02$ ) (90). The authors of the aforementioned large epidemiologic study have suggested the possibility that the benefit of allopurinol is *via* an antioxidant effect, and not necessarily *via* lowering of uric acid excretion. More recently, Goldfarb *et al.* (91) demonstrated that at 6 months, febuxostat lowers urine uric acid levels more than allopurinol, but it should be noted that the comparison was between high-dose febuxostat and standard allopurinol dosing. Regardless, in this short timeframe, no difference was seen in stone growth rates and the overall contribution of hyperuricosuria to calcium stone formation remains nebulous.

### Uric Acid Stone Disease

The three major risk factors for uric acid stone formation are low urine pH, low urine volume, and to a lesser degree, hyperuricosuria. Most often, it is the urine pH that is the key risk factor, as the urinary uric acid levels tend to be the same between normal patients and uric acid stone

formers (92). The mainstay of therapy is increased fluid intake with urinary alkalinization with alkali salts to a target pH of 6.5–7. Notably, there are no randomized controlled trials addressing the efficacy of these maneuvers, but observational studies are highly convincing. Pak *et al.* (93) followed 18 patients with uric acid stones (six pure uric acid stones and 12 with mixed calcium and uric acid stones) for an average of 2.78 years receiving treatment with potassium citrate in dosages of 30–80 mEq/d. New stone formation decreased from  $1.20 \pm 1.68$  stones per year to  $0.01 \pm 0.04$  stones per year ( $P < 0.001$ ). A small study with eight participants suggested that complete uric acid stone dissolution with potassium alkali may also be possible (94), echoing older case series (95,96), but larger trials are needed.

### Struvite Stones

Struvite stones, also known as triple phosphate or calcium magnesium ammonium phosphate, require the presence of urea-splitting bacteria for stone formation, as an exceedingly high pH is a prerequisite. These stones are notoriously difficult to treat and generally require expert urological intervention, given their potential for rapid growth and staghorn formation. If complicating circumstances dictate that complete stone removal is not feasible, urease inhibitor therapy can be used to decrease rates of stone growth. Acetohydroxamic acid is the therapy of choice in this scenario, on the basis of three randomized controlled trials demonstrating decreases in stone growth (97–99). However, its clinical use is limited because of significant side effects including gastrointestinal upset, headaches, thrombophlebitis, and rash.

### Cystine Stones

Cystinuria is a rare inherited disorder affecting renal tubular transport of cystine and dibasic amino acids, such as lysine, arginine, and ornithine. The cornerstone of therapy is adequate urine volume coupled with urinary alkalinization for a pH target  $>7$ , as this increases cystine solubility. If these maneuvers are insufficient to decrease risk of recurrent stone disease, treatment with a cysteine-binding drug may be necessary. Therapeutic options include D-penicillamine and tiopronin, although clinical effectiveness data are limited. The majority of the data comes from uncontrolled or observational trials with documented reductions in stone events of up to 75% (100). In one study (100), for example, 16 patients with cystinuria who failed treatment with fluids and alkalinization alone were started on either penicillamine (1–2 g/d) or tiopronin (800–1200 mg) in divided doses. Over an average of 78 months of follow-up, stone event rates were halved from 1.6 to 0.84 events per year. Generally D-penicillamine and tiopronin have similar efficacy (102–104), and both may be associated with significant side effects, including fever, rash, leukopenia, aplastic anemia, proteinuria, and hepatotoxicity. However, tiopronin appears to be better tolerated. If treatment with one of these agents is undertaken, it should always be in conjunction with hydration and urinary alkalinization, as the latter may also increase therapeutic effectiveness (105).

### Summary and Conclusion

Prevention of recurrent stone disease requires a multifaceted approach involving both lifestyle and pharmacologic intervention. Decisions regarding therapy are made on the basis of specific metabolic abnormalities identified by stone type and metabolic evaluation, as well as potential comorbidities. Patients with calcium stone disease associated with hypertension and/or osteoporosis, for example, would have multiple potential benefits from either a low sodium diet or thiazide therapy. Although there is only one randomized controlled trial documenting the benefit of increased fluid intake, the necessity of SS for stone formation dictates that modulation of urine volumes will affect risk. Similarly, although there is also only one high-quality randomized controlled trial of a dietary intervention with a low sodium, low animal protein, and moderate calcium diet for diminishing stone recurrence, the physiologic data strongly supports the critical importance of these parameters to minimize calciuria and stone formation. The data for oxalate restriction is more nuanced, but in the setting of significant hyperoxaluria dietary restriction, is likely warranted as long as it does not come at the expense of overall fruit and vegetable intake, which would carry its own health risks. On the pharmaceutical front, there is strong evidence of the success of both thiazides and alkali salts for reduction of stone recurrence in idiopathic calcium stone disease. Patients with uric acid stone disease reap perhaps the most benefit from urinary alkalinization, but it must be noted that our literature is limited to observational data. Data are even more limited for therapy of cystine stone disease. Given the growing burden of stone disease in the population, it is imperative that we advance our understanding of the pathogenesis of stone disease while we continue to work to improve our therapeutic armamentarium.

### Disclosures

A.L.Z. is a consultant for Retrophin.

### References

1. Scales Jr. CD, Smith AC, Hanley JM, Saigal CS; Urologic Diseases in America Project: Prevalence of kidney stones in the United States. *Eur Urol* 62: 160–165, 2012
2. Litwin MS, Saigal CS: Table 14-47: Economic impact of urologic disease. In: *Urologic Diseases in America. NIH Publication 12-7865*, Washington, DC, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Public Health Service, US Department of Health and Human Services, 2012, pp 486
3. Taylor EN, Stampfer MJ, Curhan GC: Obesity, weight gain, and the risk of kidney stones. *JAMA* 293: 455–462, 2005
4. West B, Luke A, Durazo-Arvizu RA, Cao G, Shoham D, Kramer H: Metabolic syndrome and self-reported history of kidney stones: The National Health and Nutrition Examination Survey (NHANES III) 1988–1994. *Am J Kidney Dis* 51: 741–747, 2008
5. Lieske JC, de la Vega LS, Gettman MT, Slezak JM, Bergstralh EJ, Melton 3rd LJ, Leibson CL: Diabetes mellitus and the risk of urinary tract stones: A population-based case-control study. *Am J Kidney Dis* 48: 897–904, 2006
6. Antonelli JA, Maalouf NM, Pearle MS, Lotan Y: Use of the National Health and Nutrition Examination Survey to calculate the impact of obesity and diabetes on cost and prevalence of urolithiasis in 2030. *Eur Urol* 66: 724–729, 2014
7. Fwu CW, Eggers PW, Kimmel PL, Kusek JW, Kirkali Z: Emergency department visits, use of imaging, and drugs for

- urolithiasis has increased in the United States. *Kidney Int* 83: 479–486, 2013
8. Scales Jr. CD, Lin L, Saigal CS, Bennett CJ, Ponce NA, Mangione CM, Litwin MS; NIDDK Urologic Diseases in America Project: Emergency department revisits for patients with kidney stones in California. *Acad Emerg Med* 22: 468–474, 2015
  9. Bensalah K, Tuncel A, Gupta A, Raman JD, Pearle MS, Lotan Y: Determinants of quality of life for patients with kidney stones. *J Urol* 179: 2238–2243, discussion 2243, 2008
  10. Parks JH, Coe FL: An increasing number of calcium oxalate stone events worsens treatment outcome. *Kidney Int* 45: 1722–1730, 1994
  11. Rule AD, Lieske JC, Li X, Melton 3rd LJ, Krambeck AE, Bergstralh EJ: The ROKS nomogram for predicting a second symptomatic stone episode. *J Am Soc Nephrol* 25: 2878–2886, 2014
  12. Borghi L, Meschi T, Guerra A, Novarini A: Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. *J Cardiovasc Pharmacol* 22 [Suppl 6]: S78–S86, 1993
  13. Ettinger B, Citron JT, Livermore B, Dolman LI: Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. *J Urol* 139: 679–684, 1988
  14. Laerum E: Metabolic effects of thiazide versus placebo in patients under long-term treatment for recurrent urolithiasis. *Scand J Urol Nephrol* 18: 143–149, 1984
  15. Ohkawa M, Tokunaga S, Nakashima T, Orito M, Hisazumi H: Thiazide treatment for calcium urolithiasis in patients with idiopathic hypercalciuria. *Br J Urol* 69: 571–576, 1992
  16. Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY: Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. *J Urol* 150: 1761–1764, 1993
  17. Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A: Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. *J Urol* 158: 2069–2073, 1997
  18. Hofbauer J, Höbarth K, Szabo N, Marberger M: Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis—a prospective randomized study. *Br J Urol* 73: 362–365, 1994
  19. Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A: Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: A 5-year randomized prospective study. *J Urol* 155: 839–843, 1996
  20. Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, Monga M, Penniston KL, Preminger GM, Turk TM, White JR; American Urological Association: Medical management of kidney stones: AUA guideline. *J Urol* 192: 316–324, 2014
  21. Curhan GC, Willett WC, Rimm EB, Stampfer MJ: A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. *N Engl J Med* 328: 833–838, 1993
  22. Curhan GC, Willett WC, Speizer FE, Spiegelman D, Stampfer MJ: Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. *Ann Intern Med* 126: 497–504, 1997
  23. Curhan GC, Willett WC, Knight EL, Stampfer MJ: Dietary factors and the risk of incident kidney stones in younger women: Nurses' Health Study II. *Arch Intern Med* 164: 885–891, 2004
  24. Taylor EN, Stampfer MJ, Curhan GC: Dietary factors and the risk of incident kidney stones in men: New insights after 14 years of follow-up. *J Am Soc Nephrol* 15: 3225–3232, 2004
  25. Hosking DH, Erickson SB, Van den Berg CJ, Wilson DM, Smith LH: The stone clinic effect in patients with idiopathic calcium urolithiasis. *J Urol* 130: 1115–1118, 1983
  26. Parks JH, Coe FL: Evidence for durable kidney stone prevention over several decades. *BJU Int* 103: 1238–1246, 2009
  27. Sarica K, Inal Y, Erturhan S, Yağci F: The effect of calcium channel blockers on stone regrowth and recurrence after shock wave lithotripsy. *Urol Res* 34: 184–189, 2006
  28. Qaseem A, Dallas P, Forcica MA, Starkey M, Denberg TD; Clinical Guidelines Committee of the American College of Physicians: Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults: A clinical practice guideline from the American College of Physicians. *Ann Intern Med* 161: 659–667, 2014
  29. Xu C, Zhang C, Wang XL, Liu TZ, Zeng XT, Li S, Duan XW: Self-fluid management in prevention of kidney stones: A PRISMA-compliant systematic review and dose-response meta-analysis of observational studies. *Medicine (Baltimore)* 94: e1042, 2015
  30. Raman JD, Bagrodia A, Gupta A, Bensalah K, Cadeddu JA, Lotan Y, Pearle MS: Natural history of residual fragments following percutaneous nephrostolithotomy. *J Urol* 181: 1163–1168, 2009
  31. Strem SB, Yost A, Mascha E: Clinical implications of clinically insignificant stone fragments after extracorporeal shock wave lithotripsy. *J Urol* 155: 1186–1190, 1996
  32. Worcester EM, Gillen DL, Evan AP, Parks JH, Wright K, Trumbore L, Nakagawa Y, Coe FL: Evidence that postprandial reduction of renal calcium reabsorption mediates hypercalciuria of patients with calcium nephrolithiasis. *Am J Physiol Renal Physiol* 292: F66–F75, 2007
  33. Ferraro PM, Taylor EN, Gambaro G, Curhan GC: Soda and other beverages and the risk of kidney stones. *Clin J Am Soc Nephrol* 8: 1389–1395, 2013
  34. Curhan GC, Willett WC, Rimm EB, Spiegelman D, Stampfer MJ: Prospective study of beverage use and the risk of kidney stones. *Am J Epidemiol* 143: 240–247, 1996
  35. Curhan GC, Willett WC, Speizer FE, Stampfer MJ: Beverage use and risk for kidney stones in women. *Ann Intern Med* 128: 534–540, 1998
  36. Penniston KL, Steele TH, Nakada SY: Lemonade therapy increases urinary citrate and urine volumes in patients with recurrent calcium oxalate stone formation. *Urology* 70: 856–860, 2007
  37. Kang DE, Sur RL, Haleblan GE, Fitzsimons NJ, Borawski KM, Preminger GM: Long-term lemonade based dietary manipulation in patients with hypocitraturic nephrolithiasis. *J Urol* 177: 1358–1362, discussion 1362, quiz 1591, 2007
  38. Seltzer MA, Low RK, McDonald M, Shami GS, Stoller ML: Dietary manipulation with lemonade to treat hypocitraturic calcium nephrolithiasis. *J Urol* 156: 907–909, 1996
  39. Cheungpasitporn W, Rossetti S, Friend K, Erickson SB, Lieske JC: Treatment effect, adherence, and safety of high fluid intake for the prevention of incident and recurrent kidney stones: A systematic review and meta-analysis. *J Nephrol* 29: 211–219, 2016
  40. Lotan Y, Buendia Jiménez I, Lenoir-Wijnkoop I, Daudon M, Molinier L, Tack I, Nuijten MJ: Increased water intake as a prevention strategy for recurrent urolithiasis: Major impact of compliance on cost-effectiveness. *J Urol* 189: 935–939, 2013
  41. McCauley LR, Dyer AJ, Stern K, Hicks T, Nguyen MM: Factors influencing fluid intake behavior among kidney stone formers. *J Urol* 187: 1282–1286, 2012
  42. Parks JH, Goldfischer ER, Coe FL: Changes in urine volume accomplished by physicians treating nephrolithiasis. *J Urol* 169: 863–866, 2003
  43. Taylor EN, Fung TT, Curhan GC: DASH-style diet associates with reduced risk for kidney stones. *J Am Soc Nephrol* 20: 2253–2259, 2009
  44. Borghi L, Schianchi T, Meschi T, Guerra A, Allegri F, Maggiore U, Novarini A: Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. *N Engl J Med* 346: 77–84, 2002
  45. Lemann Jr. J, Pleuss JA, Worcester EM, Hornick L, Schrab D, Hoffmann RG: Urinary oxalate excretion increases with body size and decreases with increasing dietary calcium intake among healthy adults. *Kidney Int* 49: 200–208, 1996
  46. Kleeman CR, Bohannon J, Bernstein D, Ling S, Maxwell MH: Effect of variations in sodium intake on calcium excretion in normal humans. *Proc Soc Exp Biol Med* 115: 29–32, 1964
  47. Massey LK, Whiting SJ: Dietary salt, urinary calcium, and kidney stone risk. *Nutr Rev* 53: 131–139, 1995
  48. Phillips MJ, Cooke JN: Relation between urinary calcium and sodium in patients with idiopathic hypercalciuria. *Lancet* 1: 1354–1357, 1967
  49. Burtis WJ, Gay L, Insogna KL, Ellison A, Broadus AE: Dietary hypercalciuria in patients with calcium oxalate kidney stones. *Am J Clin Nutr* 60: 424–429, 1994

50. Muldowney FP, Freaney R, Moloney MF: Importance of dietary sodium in the hypercalciuria syndrome. *Kidney Int* 22: 292–296, 1982
51. Sakhaee K, Harvey JA, Padalino PK, Whitson P, Pak CY: The potential role of salt abuse on the risk for kidney stone formation. *J Urol* 150: 310–312, 1993
52. Nouvenne A, Meschi T, Prati B, Guerra A, Allegri F, Vezzoli G, Soldati L, Gambaro G, Maggiore U, Borghi L: Effects of a low-salt diet on idiopathic hypercalciuria in calcium-oxalate stone formers: A 3-mo randomized controlled trial. *Am J Clin Nutr* 91: 565–570, 2010
53. Curhan GC, Willett WC, Speizer FE, Stampfer MJ: Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. *Kidney Int* 59: 2290–2298, 2001
54. Pak CY, Adams-Huet B, Poindexter JR, Pearle MS, Peterson RD, Moe OW: Rapid Communication: Relative effect of urinary calcium and oxalate on saturation of calcium oxalate. *Kidney Int* 66: 2032–2037, 2004
55. Baggio B, Gambaro G, Favaro S, Borsatti A: Prevalence of hyperoxaluria in idiopathic calcium oxalate kidney stone disease. *Nephron* 35: 11–14, 1983
56. Hoppe B, Langman CB: A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria. *Pediatr Nephrol* 18: 986–991, 2003
57. Taylor EN, Curhan GC: Oxalate intake and the risk for nephrolithiasis. *J Am Soc Nephrol* 18: 2198–2204, 2007
58. Taylor EN, Curhan GC: Determinants of 24-hour urinary oxalate excretion. *Clin J Am Soc Nephrol* 3: 1453–1460, 2008
59. Siener R, Ebert D, Nicolay C, Hesse A: Dietary risk factors for hyperoxaluria in calcium oxalate stone formers. *Kidney Int* 63: 1037–1043, 2003
60. Siener R, Schade N, Nicolay C, von Unruh GE, Hesse A: The efficacy of dietary intervention on urinary risk factors for stone formation in recurrent calcium oxalate stone patients. *J Urol* 173: 1601–1605, 2005
61. Holmes RP, Assimos DG, Goodman HO: Genetic and dietary influences on urinary oxalate excretion. *Urol Res* 26: 195–200, 1998
62. Holmes RP, Goodman HO, Assimos DG: Contribution of dietary oxalate to urinary oxalate excretion. *Kidney Int* 59: 270–276, 2001
63. Penniston KL, Nakada SY: Effect of dietary changes on urinary oxalate excretion and calcium oxalate supersaturation in patients with hyperoxaluric stone formation. *Urology* 73: 484–489, 2009
64. Laminski NA, Meyers AM, Kruger M, Sonnekus MI, Margolius LP: Hyperoxaluria in patients with recurrent calcium oxalate calculi: Dietary and other risk factors. *Br J Urol* 68: 454–458, 1991
65. Lieske JC, Tremaine WJ, De Simone C, O'Connor HM, Li X, Bergstralh EJ, Goldfarb DS: Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. *Kidney Int* 78: 1178–1185, 2010
66. Ferraro PM, Mandel EL, Curhan GC, Gambaro G, Taylor EN: Dietary protein and potassium, diet-dependent net acid load, and risk of incident kidney stones. *Clin J Am Soc Nephrol* 11: 1834–1844, 2016
67. Fenton TR, Eliasziw M, Lyon AW, Tough SC, Hanley DA: Meta-analysis of the quantity of calcium excretion associated with the net acid excretion of the modern diet under the acid-ash diet hypothesis. *Am J Clin Nutr* 88: 1159–1166, 2008
68. Dussol B, Iovanna C, Rotily M, Morange S, Leonetti F, Dupuy P, Vazi A, Saveanu A, Loundou A, Berland Y: A randomized trial of low-animal-protein or high-fiber diets for secondary prevention of calcium nephrolithiasis. *Nephron Clin Pract* 110: c185–c194, 2008
69. Hiatt RA, Ettinger B, Caan B, Quesenberry Jr. CP, Duncan D, Citron JT: Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. *Am J Epidemiol* 144: 25–33, 1996
70. Bergsland KJ, Worcester EM, Coe FL: Role of proximal tubule in the hypocalciuric response to thiazide of patients with idiopathic hypercalciuria. *Am J Physiol Renal Physiol* 305: F592–F599, 2013
71. Nijenhuis T, Vallon V, van der Kemp AW, Löffing J, Hoenderop JG, Bindels RJ: Enhanced passive Ca<sup>2+</sup> reabsorption and reduced Mg<sup>2+</sup> channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. *J Clin Invest* 115: 1651–1658, 2005
72. Coe FL, Parks JH, Bushinsky DA, Langman CB, Favus MJ: Chlorthalidone promotes mineral retention in patients with idiopathic hypercalciuria. *Kidney Int* 33: 1140–1146, 1988
73. Bolland MJ, Ames RW, Horne AM, Orr-Walker BJ, Gamble GD, Reid IR: The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. *Osteoporos Int* 18: 479–486, 2007
74. Laerum E, Larsen S: Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. *Acta Med Scand* 215: 383–389, 1984
75. Wilson DR, Strauss AL, Manuel MA: Comparison of medical treatments for the prevention of recurrent calcium nephrolithiasis. *Urol Res* 12: 39, 1984
76. Robertson WG, Peacock M, Selby PL, Williams RE, Clark P, Chisholm GD, Hargreaves TB, Rose MB, Wilkinson H: A multicenter trial to evaluate three treatments for recurrent idiopathic calcium stone disease - A preliminary report. In: *Urolithiasis and Related Clinical Research*, edited by Schwille PO, Smith LH, Robertson WG, Vahlensieck W, New York, Plenum Press, 1985, pp 545–548
77. Fernández-Rodríguez A, Arrabal-Martín M, García-Ruiz MJ, Arrabal-Polo MA, Pichardo-Pichardo S, Zuluaga-Gómez A: [The role of thiazides in the prophylaxis of recurrent calcium lithiasis]. *Actas Urol Esp* 30: 305–309, 2006
78. Brocks P, Dahl C, Wolf H, Transbøl I: Do thiazides prevent recurrent idiopathic renal calcium stones? *Lancet* 2: 124–125, 1981
79. Scholz D, Schwille PO, Sigel A: Double-blind study with thiazide in recurrent calcium lithiasis. *J Urol* 128: 903–907, 1982
80. Mortensen JT, Schultz A, Ostergaard AH: Thiazides in the prophylactic treatment of recurrent idiopathic kidney stones. *Int Urol Nephrol* 18: 265–269, 1986
81. Vigen R, Weideman RA, Reilly RF: Thiazides diuretics in the treatment of nephrolithiasis: Are we using them in an evidence-based fashion? *Int Urol Nephrol* 43: 813–819, 2011
82. Soygür T, Akbay A, Küpeli S: Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: A randomized controlled trial. *J Endourol* 16: 149–152, 2002
83. Lojanapiwat B, Tanthanuch M, Pripathanont C, Ratchanon S, Srinualnad S, Taweemonkongsap T, Kanyok S, Lammongkolkul S: Alkaline citrate reduces stone recurrence and regrowth after shockwave lithotripsy and percutaneous nephrolithotomy. *Int Braz J Urol* 37: 611–616, 2011
84. Pinheiro VB, Baxmann AC, Tiselius HG, Heilberg IP: The effect of sodium bicarbonate upon urinary citrate excretion in calcium stone formers. *Urology* 82: 33–37, 2013
85. Parks JH, Worcester EM, Coe FL, Evan AP, Lingeman JE: Clinical implications of abundant calcium phosphate in routinely analyzed kidney stones. *Kidney Int* 66: 777–785, 2004
86. Preminger GM, Sakhaee K, Skurla C, Pak CY: Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. *J Urol* 134: 20–23, 1985
87. Coe FL, Worcester EM, Evan AP: Idiopathic hypercalciuria and formation of calcium renal stones. *Nat Rev Nephrol* 12: 519–533, 2016
88. Pak CY, Barilla DE, Holt K, Brinkley L, Tolentino R, Zerwekh JE: Effect of oral purine load and allopurinol on the crystallization of calcium salts in urine of patients with hyperuricosuric calcium urolithiasis. *Am J Med* 65: 593–599, 1978
89. Curhan GC, Taylor EN: 24-h uric acid excretion and the risk of kidney stones. *Kidney Int* 73: 489–496, 2008
90. Ettinger B, Tang A, Citron JT, Livermore B, Williams T: Randomized trial of allopurinol in the prevention of calcium oxalate calculi. *N Engl J Med* 315: 1386–1389, 1986
91. Goldfarb DS, MacDonald PA, Gunawardhana L, Chefo S, McLean L: Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones. *Clin J Am Soc Nephrol* 8: 1960–1967, 2013

92. Pak CY, Sakhaee K, Peterson RD, Poindexter JR, Frawley WH: Biochemical profile of idiopathic uric acid nephrolithiasis. *Kidney Int* 60: 757–761, 2001
93. Pak CY, Sakhaee K, Fuller C: Successful management of uric acid nephrolithiasis with potassium citrate. *Kidney Int* 30: 422–428, 1986
94. Trinchieri A, Esposito N, Castelnovo C: Dissolution of radiolucent renal stones by oral alkalinization with potassium citrate/potassium bicarbonate. *Arch Ital Urol Androl* 81: 188–191, 2009
95. Moran ME, Abrahams HM, Burday DE, Greene TD: Utility of oral dissolution therapy in the management of referred patients with secondarily treated uric acid stones. *Urology* 59: 206–210, 2002
96. Kursh ED, Resnick MI: Dissolution of uric acid calculi with systemic alkalization. *J Urol* 132: 286–287, 1984
97. Griffith DP, Gleeson MJ, Lee H, Longuet R, Deman E, Earle N: Randomized, double-blind trial of Lithostat (acetohydroxamic acid) in the palliative treatment of infection-induced urinary calculi. *Eur Urol* 20: 243–247, 1991
98. Griffith DP, Khonsari F, Skurnick JH, James KE: A randomized trial of acetohydroxamic acid for the treatment and prevention of infection-induced urinary stones in spinal cord injury patients. *J Urol* 140: 318–324, 1988
99. Williams JJ, Rodman JS, Peterson CM: A randomized double-blind study of acetohydroxamic acid in struvite nephrolithiasis. *N Engl J Med* 311: 760–764, 1984
100. Singer A, Das S: Cystinuria: A review of the pathophysiology and management. *J Urol* 142: 669–673, 1989
101. Chow GK, Strem SB: Medical treatment of cystinuria: Results of contemporary clinical practice. *J Urol* 156: 1576–1578, 1996
102. Lindell A, Denneberg T, Hellgren E, Jeppsson JO, Tiselius HG: Clinical course and cystine stone formation during tiopronin treatment. *Urol Res* 23: 111–117, 1995
103. Pak CY, Fuller C, Sakhaee K, Zerwekh JE, Adams BV: Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine. *J Urol* 136: 1003–1008, 1986
104. Goldfarb DS, Coe FL, Asplin JR: Urinary cystine excretion and capacity in patients with cystinuria. *Kidney Int* 69: 1041–1047, 2006
105. Asplin DM, Asplin JR: The Interaction of thiol drugs and urine pH in the treatment of cystinuria. *J Urol* 189: 2147–2151, 2013

Published online ahead of print. Publication date available at [www.cjasn.org](http://www.cjasn.org).